Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nabriva Therapeutics to Present Data at IDWeek 2021
Details : XENLETA® (lefamulin) is first-in-class pleuromutilin antibiotic for treatment of community-acquired bacterial pneumonia (CABP). It's in vitro activity of lefamulin against Staphylococcus aureus isolated from lower respiratory tract of children with cyst...
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable